AR and neoplasm: In their research, Barton et al. [67] suggested that AR testing should become the standard in tumor analysis and that TNBC should be defined as either AR+ TNBC or “quadruple negative” disease to highlight the presence of AR as a potential target for the design and application of new drugs.